Comparing two drug combinations for limited-stage small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests whether adding a new drug, tarlatamab, to the standard treatment durvalumab helps people with limited-stage small cell lung cancer more than durvalumab alone. It is for patients who have already completed chemotherapy and radiation without the cancer growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with limited-stage small cell lung cancer (cancer that has not spread beyond one lung area).
- You have completed 3 to 4 cycles of chemotherapy (with a platinum drug and etoposide) and radiation therapy, and the cancer has not progressed.
- You are at least 18 years old.
- You are able to perform daily activities with little or no help (ECOG score 0 or 1).
- You have adequate organ function (kidney, liver, heart, and blood counts) as determined by tests.
- You have not had prior treatment with certain immune therapies (like PD-1/PD-L1 inhibitors) or DLL3-targeted drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy medicine called tarlatamab given as maintenance therapy after initial treatment for limited-stage small cell lung cancer. It aims to keep the cancer from coming back.
This trial tests long-term use of durvalumab (an immunotherapy drug) after standard chemotherapy and radiation for limited-stage small cell lung cancer. It may keep the cancer from coming back.
This study tests three experimental drugs (tarlatamab, ZL-1310, and sometimes an immune-boosting drug) together to treat small cell lung cancer. The goal is to see if this combination can slow or shrink the cancer and help you live longer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests a new drug called tarlatamab for people with extensive-stage small-cell lung cancer who are too unwell for standard treatments. It aims to see if the drug can help shrink tumors and improve outcomes.
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.